Patents by Inventor Pierre Stallforth

Pierre Stallforth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240391958
    Abstract: The present invention relates to a new class of antibiotic substances, designated as keanumycins for their versatility in fighting and controlling fungi and amoebas in mammals and plants.
    Type: Application
    Filed: May 23, 2024
    Publication date: November 28, 2024
    Inventors: Sebastian PFLANZE, Sebastian GÖTZE, Pierre STALLFORTH
  • Patent number: 10588962
    Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: March 17, 2020
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., UNIVERSITÄTSSPITAL BASEL
    Inventors: Peter H. Seeberger, Pierre Stallforth, Gennaro De Libero, Marco Cavallari
  • Publication number: 20150238597
    Abstract: The present invention relates to the field of synthesizing and biologically evaluating of a novel class of carbohydrate-based vaccines. The new vaccines consist of a multi-modular structure which allows applying the vaccine to a whole variety of pathogenes. This method allows preparing vaccines against all pathogens expressing immunogenic carbohydrate antigens. As conjugation of antigenic carbohydrates to proteins is not required the conjugate vaccine is particularly heat stable. No refrigeration is required, a major drawback of protein-based vaccines.
    Type: Application
    Filed: March 19, 2013
    Publication date: August 27, 2015
    Applicants: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., UNIVERSITÄTSSPITAL BASEL
    Inventors: Peter H. Seeberger, Pierre Stallforth, Gennaro De Libero, Marco Cavallari